[go: up one dir, main page]

WO2003006002A8 - Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases - Google Patents

Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Info

Publication number
WO2003006002A8
WO2003006002A8 PCT/US2002/022449 US0222449W WO03006002A8 WO 2003006002 A8 WO2003006002 A8 WO 2003006002A8 US 0222449 W US0222449 W US 0222449W WO 03006002 A8 WO03006002 A8 WO 03006002A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
methods
tubulin binding
binding agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/022449
Other languages
French (fr)
Other versions
WO2003006002A9 (en
WO2003006002A1 (en
Inventor
David Sherris
Mark Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15958102A priority Critical patent/IL159581A0/en
Priority to CN028139917A priority patent/CN1527704B/en
Priority to CA2453442A priority patent/CA2453442C/en
Priority to MXPA04000386A priority patent/MXPA04000386A/en
Priority to JP2003511808A priority patent/JP2004536847A/en
Priority to KR10-2004-7000464A priority patent/KR20040030042A/en
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Priority to EP02756487A priority patent/EP1406600A4/en
Publication of WO2003006002A1 publication Critical patent/WO2003006002A1/en
Priority to ZA2004/00210A priority patent/ZA200400210B/en
Anticipated expiration legal-status Critical
Publication of WO2003006002A8 publication Critical patent/WO2003006002A8/en
Publication of WO2003006002A9 publication Critical patent/WO2003006002A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention is directed to the administration of vascular targeting agents, particularly a tubulin binding agent, for the treatment of ocular neovascularization, ocular tumors, and conditions such as diabetic retinopathy, retinopathy of prematurity, retinoblastoma and macular degeneration.
PCT/US2002/022449 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases Ceased WO2003006002A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP02756487A EP1406600A4 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CA2453442A CA2453442C (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
MXPA04000386A MXPA04000386A (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases.
JP2003511808A JP2004536847A (en) 2001-07-13 2002-07-15 Compositions and methods for administering tubulin binding agents for the treatment of ocular diseases
KR10-2004-7000464A KR20040030042A (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
IL15958102A IL159581A0 (en) 2002-05-03 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CN028139917A CN1527704B (en) 2001-07-13 2002-07-15 Compositions and method of administering tubulin binding agents for the treatment of ocular diseases
ZA2004/00210A ZA200400210B (en) 2001-07-13 2004-01-12 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US60/386,227 2001-07-13
US37784502P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
US60/377,845 2002-05-03
US60/377,847 2002-05-03
US60/377,556 2002-05-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/344,886 A-371-Of-International US20030181531A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US10/732,680 Continuation-In-Part US20040229960A1 (en) 2001-07-13 2003-12-09 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (3)

Publication Number Publication Date
WO2003006002A1 WO2003006002A1 (en) 2003-01-23
WO2003006002A8 true WO2003006002A8 (en) 2004-05-27
WO2003006002A9 WO2003006002A9 (en) 2004-07-22

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022449 Ceased WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Country Status (8)

Country Link
EP (1) EP1406600A4 (en)
JP (2) JP2004536847A (en)
KR (1) KR20040030042A (en)
CN (1) CN1527704B (en)
CA (1) CA2453442C (en)
NZ (1) NZ575466A (en)
WO (1) WO2003006002A1 (en)
ZA (1) ZA200400210B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (en) * 2003-04-09 2007-11-07 日信工業株式会社 Carbon fiber composite material and method for producing the same
CA2766178A1 (en) * 2009-07-02 2011-01-06 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
WO2011022772A1 (en) 2009-08-27 2011-03-03 Bionomics Limited Combination therapy for treating proliferative diseases
JP2013502440A (en) * 2009-08-27 2013-01-24 バイオノミックス リミテッド Treatment of macular degeneration
US9371432B2 (en) * 2012-08-02 2016-06-21 Amril Ag Natural rubber containing nanocarbon
CN113577020B (en) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 Intravitreal injection, preparation method and application thereof
CN113520995B (en) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 An ion-sensitive ophthalmic in-situ gel, its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
WO1999035150A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
AU776511B2 (en) * 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
EP1406600A4 (en) 2007-06-06
WO2003006002A9 (en) 2004-07-22
WO2003006002A1 (en) 2003-01-23
KR20040030042A (en) 2004-04-08
EP1406600A1 (en) 2004-04-14
CA2453442A1 (en) 2003-01-23
ZA200400210B (en) 2005-06-29
JP2004536847A (en) 2004-12-09
NZ575466A (en) 2011-01-28
CN1527704A (en) 2004-09-08
CA2453442C (en) 2011-02-01
JP2009132738A (en) 2009-06-18
CN1527704B (en) 2011-05-18

Similar Documents

Publication Publication Date Title
WO2002058730A3 (en) Compositions for treatment of ocular neovascularization
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
WO2001051087A3 (en) Novel treatment for eye disease
WO2003057259A3 (en) Indocyanine green (icg) compositions
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2006059357A3 (en) Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2002087563A3 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
WO2002064083A3 (en) Synthesis of 3-amino-thalidomide and its enantiomers
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2003006002A8 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2004016214A3 (en) Methods and compositions for treatment of macular and retinal disease
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
WO2007089673A3 (en) Compositions and methods for treatment of ophthalmic diseases and disorders
TW200628473A (en) Novel heterocycles
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
WO2002051379A3 (en) Thixotropic nasal spray
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10344886

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159581

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003511808

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002756487

Country of ref document: EP

Ref document number: 2004/00210

Country of ref document: ZA

Ref document number: 2453442

Country of ref document: CA

Ref document number: 20028139917

Country of ref document: CN

Ref document number: 530517

Country of ref document: NZ

Ref document number: 200400210

Country of ref document: ZA

Ref document number: 1020047000464

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500060

Country of ref document: PH

Ref document number: PA/a/2004/000386

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002322494

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002756487

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 04/2003 UNDER (30) REPLACE "NOT FURNISHED, 13 JULY 2001 (13.07.2001), US" BY "60/386,227, 13 JULY 2001 (13.07.2001), US"; REPLACE "NOT FURNISHED, 3 MAY 2002 (03.05.2002), US" BY "60/377,847, 3 MAY 2002 (03.05.2002), US"

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE